This is a summary of the European public assessment report (EPAR) for Yttriga. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Yttriga.
Therapeutic Indication
To be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide. Radiopharmaceutical precursor \- Not intended for direct use in patients.
Therapeutic Area (MeSH)
ATC Code
V09
ATC Item
N/A
Pharmacotherapeutic Group
Diagnostic radiopharmaceuticals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| yttrium (90Y) chloride | N/A | yttrium (90Y) chloride |
EMA Name
Yttriga
Medicine Name
Yttriga
Aliases
N/ANo risk management plan link.
